secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0000950170-24-124141
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports Q3 net loss of $2.2M; cash $6.5M into 2025
-------------------------------------------------------------------------

- Net loss Q3 2024: $2.2M ($0.84 per share) vs $2.6M loss in Q3 2023; nine-month net loss $13.3M vs net income $2.1M in prior year.
- Cash and cash equivalents $6.5M as of Sep 30, 2024, down from $12.0M at Dec 31, 2023; raised $3.8M from warrant exercise in Aug 2024.
- Clinical-stage biotech advancing Gemini; expects FDA IND acceptance to start Phase 1b in CKD patients; cash runway into 2025.
- Net cash used in operations nine months: $14.6M vs $5.3M in 2023; cash burn increased significantly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024124141/0000950170-24-124141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024124141/revb-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer